SB-1102
AN ACT CONCERNING PHARMACIES AND PHARMACISTS.
AMENDMENT
LCO No.: 7349
File Copy No.: 221
Senate Calendar No.: 150

OFA Fiscal Note

State Impact:

<table>
<thead>
<tr>
<th>Agency Affected</th>
<th>Fund-Effect</th>
<th>FY 24 $</th>
<th>FY 25 $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public Health, Dept.</td>
<td>IF - Savings</td>
<td>25,000</td>
<td>25,000</td>
</tr>
<tr>
<td>Public Health, Dept.</td>
<td>IF - Cost</td>
<td>25,000</td>
<td>25,000</td>
</tr>
<tr>
<td>TOTAL</td>
<td>IF - None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

Note: IF=Insurance Fund

Municipal Impact: None

Explanation

Section 17, which requires the Department of Public Health to establish a statewide human immunodeficiency virus pre- and post-exposure prophylaxis drug assistance program, using appropriated AIDS Services account funding equal to or greater than $25,000 annually, and eliminates a victims of sexual assault post-exposure prophylaxis program that costs $25,000 annually, results in a net zero fiscal impact to the agency.

Sections 1 - 16 make various changes to statutes concerning pharmacists and consumer access to medications resulting in no fiscal impact to the State or municipalities.

The preceding Fiscal Impact statement is prepared for the benefit of the members of the General Assembly, solely for the purposes of information, summarization and explanation and does not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

Primary Analyst: RDP
Contributing Analyst(s): ME

5/4/23